Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

recruiting267%
withdrawn133%

Recent Activity

2 active trials
Showing 3 of 3
recruiting

Zephyr Valve Japan Post-Marketing Surveillance

NCT06332885
recruitingphase_2

Cell Therapy Associated With Endobronchial Valve

NCT04018729
withdrawnphase_3

Sequential Endoscopic Lung Volume Reduction

NCT00613860

Clinical Trials (3)

Showing 3 of 3 trials
NCT06332885

Zephyr Valve Japan Post-Marketing Surveillance

Recruiting
NCT04018729Phase 2

Cell Therapy Associated With Endobronchial Valve

Recruiting
NCT00613860Phase 3

Sequential Endoscopic Lung Volume Reduction

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3